vs
Doximity, Inc.（DOCS）与IONIS PHARMACEUTICALS INC（IONS）财务数据对比。点击上方公司名可切换其他公司
IONIS PHARMACEUTICALS INC的季度营收约是Doximity, Inc.的1.1倍（$203.3M vs $185.1M），Doximity, Inc.净利率更高（33.3% vs -112.8%，领先146.1%），Doximity, Inc.同比增速更快（9.8% vs -10.3%），过去两年IONIS PHARMACEUTICALS INC的营收复合增速更高（30.4% vs 25.2%）
Doximity Inc成立于2010年，是面向医疗专业人士的线上社交服务平台，为平台会员提供精选医疗资讯、远程医疗工具，以及病例协作相关功能，助力医疗从业者高效交流信息、开展诊疗相关工作。
IONIS制药是1989年成立的生物科技企业，总部位于美国加利福尼亚州卡尔斯巴德，专注于反义疗法、RNA干扰及CRISPR疗法的研发，2015年12月前曾以Isis制药的名称运营。
DOCS vs IONS — 直观对比
营收规模更大
IONS
是对方的1.1倍
$185.1M
营收增速更快
DOCS
高出20.0%
-10.3%
净利率更高
DOCS
高出146.1%
-112.8%
两年增速更快
IONS
近两年复合增速
25.2%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $185.1M | $203.3M |
| 净利润 | $61.6M | $-229.4M |
| 毛利率 | 89.9% | 96.1% |
| 营业利润率 | 38.9% | -105.5% |
| 净利率 | 33.3% | -112.8% |
| 营收同比 | 9.8% | -10.3% |
| 净利润同比 | -18.1% | -119.8% |
| 每股收益（稀释后） | $0.31 | $-1.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCSIONS
| Q4 25 | $185.1M | $203.3M | ||
| Q3 25 | $168.5M | $156.7M | ||
| Q2 25 | $145.9M | $452.0M | ||
| Q1 25 | $138.3M | $131.6M | ||
| Q4 24 | $168.6M | $226.6M | ||
| Q3 24 | $136.8M | $133.8M | ||
| Q2 24 | $126.7M | $225.3M | ||
| Q1 24 | $118.1M | $119.5M |
净利润DOCSIONS
| Q4 25 | $61.6M | $-229.4M | ||
| Q3 25 | $62.1M | $-128.6M | ||
| Q2 25 | $53.3M | $123.6M | ||
| Q1 25 | $62.5M | $-146.9M | ||
| Q4 24 | $75.2M | $-104.3M | ||
| Q3 24 | $44.2M | $-140.5M | ||
| Q2 24 | $41.4M | $-66.3M | ||
| Q1 24 | $40.6M | $-142.8M |
毛利率DOCSIONS
| Q4 25 | 89.9% | 96.1% | ||
| Q3 25 | 90.3% | 98.5% | ||
| Q2 25 | 89.2% | 99.1% | ||
| Q1 25 | 89.5% | 98.9% | ||
| Q4 24 | 91.6% | 98.3% | ||
| Q3 24 | 90.0% | 99.2% | ||
| Q2 24 | 89.3% | 98.2% | ||
| Q1 24 | 89.4% | 98.2% |
营业利润率DOCSIONS
| Q4 25 | 38.9% | -105.5% | ||
| Q3 25 | 37.8% | -102.2% | ||
| Q2 25 | 37.4% | 30.9% | ||
| Q1 25 | 35.2% | -111.6% | ||
| Q4 24 | 47.4% | -48.9% | ||
| Q3 24 | 38.8% | -111.1% | ||
| Q2 24 | 36.4% | -29.3% | ||
| Q1 24 | 35.5% | -125.1% |
净利率DOCSIONS
| Q4 25 | 33.3% | -112.8% | ||
| Q3 25 | 36.8% | -82.1% | ||
| Q2 25 | 36.5% | 27.3% | ||
| Q1 25 | 45.2% | -111.6% | ||
| Q4 24 | 44.6% | -46.1% | ||
| Q3 24 | 32.3% | -105.0% | ||
| Q2 24 | 32.7% | -29.4% | ||
| Q1 24 | 34.4% | -119.5% |
每股收益（稀释后）DOCSIONS
| Q4 25 | $0.31 | $-1.35 | ||
| Q3 25 | $0.31 | $-0.80 | ||
| Q2 25 | $0.27 | $0.70 | ||
| Q1 25 | $0.31 | $-0.93 | ||
| Q4 24 | $0.37 | $-0.66 | ||
| Q3 24 | $0.22 | $-0.95 | ||
| Q2 24 | $0.21 | $-0.45 | ||
| Q1 24 | $0.20 | $-0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.8M | $2.7B |
| 总债务越低越好 | — | $1.8B |
| 股东权益账面价值 | $979.3M | $489.1M |
| 总资产 | $1.2B | $3.5B |
| 负债/权益比越低杠杆越低 | — | 3.71× |
8季度趋势，按日历期对齐
现金及短期投资DOCSIONS
| Q4 25 | $64.8M | $2.7B | ||
| Q3 25 | $169.2M | $2.2B | ||
| Q2 25 | $137.3M | $2.3B | ||
| Q1 25 | $209.6M | $2.1B | ||
| Q4 24 | $165.3M | $2.3B | ||
| Q3 24 | $184.2M | $2.5B | ||
| Q2 24 | $111.4M | $2.1B | ||
| Q1 24 | $96.8M | $2.2B |
总债务DOCSIONS
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益DOCSIONS
| Q4 25 | $979.3M | $489.1M | ||
| Q3 25 | $1.1B | $618.0M | ||
| Q2 25 | $1.0B | $631.7M | ||
| Q1 25 | $1.1B | $475.7M | ||
| Q4 24 | $1.0B | $588.4M | ||
| Q3 24 | $961.2M | $662.5M | ||
| Q2 24 | $913.6M | $263.7M | ||
| Q1 24 | $901.4M | $296.5M |
总资产DOCSIONS
| Q4 25 | $1.2B | $3.5B | ||
| Q3 25 | $1.3B | $3.0B | ||
| Q2 25 | $1.2B | $3.0B | ||
| Q1 25 | $1.3B | $2.8B | ||
| Q4 24 | $1.2B | $3.0B | ||
| Q3 24 | $1.1B | $3.1B | ||
| Q2 24 | $1.1B | $2.7B | ||
| Q1 24 | $1.1B | $2.8B |
负债/权益比DOCSIONS
| Q4 25 | — | 3.71× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.13× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.9M | $-137.7M |
| 自由现金流经营现金流 - 资本支出 | — | $-159.0M |
| 自由现金流率自由现金流/营收 | — | -78.2% |
| 资本支出强度资本支出/营收 | — | 10.5% |
| 现金转化率经营现金流/净利润 | 0.99× | — |
| 过去12个月自由现金流最近4个季度 | — | $-320.0M |
8季度趋势，按日历期对齐
经营现金流DOCSIONS
| Q4 25 | $60.9M | $-137.7M | ||
| Q3 25 | $93.9M | $-131.4M | ||
| Q2 25 | $62.1M | $151.3M | ||
| Q1 25 | $98.5M | $-150.8M | ||
| Q4 24 | $65.2M | $-116.1M | ||
| Q3 24 | $68.3M | $-115.0M | ||
| Q2 24 | $41.2M | $-119.9M | ||
| Q1 24 | $63.9M | $-149.9M |
自由现金流DOCSIONS
| Q4 25 | — | $-159.0M | ||
| Q3 25 | — | $-136.7M | ||
| Q2 25 | — | $139.0M | ||
| Q1 25 | — | $-163.4M | ||
| Q4 24 | — | $-141.6M | ||
| Q3 24 | — | $-124.0M | ||
| Q2 24 | — | $-126.1M | ||
| Q1 24 | — | $-154.4M |
自由现金流率DOCSIONS
| Q4 25 | — | -78.2% | ||
| Q3 25 | — | -87.2% | ||
| Q2 25 | — | 30.8% | ||
| Q1 25 | — | -124.1% | ||
| Q4 24 | — | -62.5% | ||
| Q3 24 | — | -92.7% | ||
| Q2 24 | — | -56.0% | ||
| Q1 24 | — | -129.2% |
资本支出强度DOCSIONS
| Q4 25 | — | 10.5% | ||
| Q3 25 | — | 3.4% | ||
| Q2 25 | — | 2.7% | ||
| Q1 25 | 0.0% | 9.6% | ||
| Q4 24 | 0.0% | 11.3% | ||
| Q3 24 | 0.0% | 6.8% | ||
| Q2 24 | 0.0% | 2.8% | ||
| Q1 24 | 0.0% | 3.8% |
现金转化率DOCSIONS
| Q4 25 | 0.99× | — | ||
| Q3 25 | 1.51× | — | ||
| Q2 25 | 1.16× | 1.22× | ||
| Q1 25 | 1.58× | — | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 1.57× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
IONS
| Products | $58.0M | 29% |
| Spinraza Royalties | $54.0M | 27% |
| Collaborative Agreement Revenue | $52.4M | 26% |
| Wainus Royalties | $16.0M | 8% |
| Wainua Joint Development Revenue | $9.6M | 5% |
| Other Commercial | $7.6M | 4% |
| Other Royalties | $5.7M | 3% |
